What's Happening?
A clinical trial has demonstrated that an eye implant paired with smart glasses can restore some central vision in patients with age-related macular degeneration (AMD). The implant, developed by Science Corporation, is a 2-by-2-millimeter device made
of photovoltaic solar panels, surgically implanted under the retina. The smart glasses transmit images to the implant using near-infrared light, which then sends electrical signals to the optic nerve. The trial involved 38 patients, with 80% showing improved vision after one year. The technology, originally developed by Pixium Vision, was acquired by Science Corporation after Pixium ran out of funding.
Why It's Important?
This breakthrough offers hope for millions affected by AMD, a leading cause of blindness in older adults. The ability to restore vision, even partially, can significantly enhance the quality of life for patients, allowing them to perform daily activities like reading and navigating their environment. The success of this trial could lead to wider adoption of the technology, providing a new treatment option for those with AMD.
What's Next?
Science Corporation is seeking regulatory approval to market the device in Europe. Further research and development may focus on improving the technology to enhance visual outcomes and expand its use to other forms of vision impairment. The company may also explore partnerships to bring the technology to a broader market.
